Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis

Nephrology Dialysis Transplantation

Volumn 26, Issue 12, 2011, Pages 4073-4078

  Tokgoz, Bulent ^a   Ucar, Cahit ^a   Kocyigit, Ismail ^a   Somdas, Mehmet ^a   Unal, Aydin ^a   Vural, Alperen ^a   Sipahioglu, Murat ^a   Oymak, Oktay ^a   Utas, Cengiz ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

amikacin; CAPD peritonitis; NAC; ototoxicity; vancomycin

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; ANTIBIOTIC AGENT; ASIST; CEFAZOLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ARTICLE; AUDITORY SYSTEM FUNCTION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DRUG INDUCED DISEASE; EAR PROTECTION; FOLLOW UP; HEARING IMPAIRMENT; HEARING LOSS; HEARING TEST; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; OPEN STUDY; OTOTOXICITY; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UREMIA;

ACETYLCYSTEINE; AMIKACIN; ANTI-BACTERIAL AGENTS; EAR DISEASES; FREE RADICAL SCAVENGERS; HUMANS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 82255185502     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr211     Document Type: Article

References (34)

1. Fried LF, Bernardini J, Johnston JR et al. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 2176-2182 (Pubitemid 27468247)
2. Woodrow G, Turney JH, Brownjohn AM. Technique failure in peritoneal dialysis and its impact on patient survival. Perit Dial Int 1997; 17: 360-364 (Pubitemid 27470211)
3. Bayston R, Andrews M, Rigg K et al. Recurrent infection and catheter loss in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1999; 19: 550-555 (Pubitemid 30015569)
4. Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: Gram-negatives versus gram-positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52: 524-529 (Pubitemid 27359599)
5. Piraino B, Bernardini J, Sorkin M. The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections, and catheter loss in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1986; 8: 436-440 (Pubitemid 17031997)
6. Sipahioglu MH, Aybal A, Unal A et al. Patient and technique survival and factors affecting mortality on peritoneal dialysis in Turkey: 12 years' experience in a single center. Perit Dial Int 2008; 28: 238-245 (Pubitemid 352003037)
7. Piraino B, Bernardini J, Sorkin M. Catheter infections as a factor in the transfer of continuous ambulatory peritoneal dialysis patients to hemodialysis. Am J Kidney Dis 1989; 13: 365-369 (Pubitemid 19135931)
8. Keane WF, Everett ED, Golper TA et al. Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis. Perit Dial Int 1993; 13: 14-28 (Pubitemid 23091318)
9. Keane WF, Alexander SR, Bailie GR et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996; 16: 557-573 (Pubitemid 127541295)
10. Keane WF, Bailie GR, Boeschoten E et al. Adult peritoneal dialysisrelated peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20: 396-411
11. Piraino B, Bailie GR, Bernardini J et al. ISPD Ad Hoc Advisory Committee. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-131 (Pubitemid 40484720)
12. Tokgoz B, Somdas MA, Ucar C et al. Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD. Ren Fail 2010; 32: 179-184
13. Sinswat P, Wu W, Sha S et al. Protection from ototoxicity of intraperitoneal gentamicin in guinea pigs. Kidney Int 2000; 58: 2525-2532
14. Klein M, Koedel U, Pfister H et al. Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy. Ann Neurol 2003; 54: 451-458 (Pubitemid 37176539)
15. Feghali J, Liu W, Van De Water T. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 2001; 111: 1147-1155 (Pubitemid 32625400)
16. Mazzon E, Britti D, De Sarro A et al. Effect of N-acetylcysteine on gentamycin-mediated nephropathy in rats. Eur J Pharmacol 2001; 424: 75-83 (Pubitemid 32695557)
17. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994; 36 (Suppl): 11-19
18. Gilbert D. Aminoglycosides. In: Mandell GL, Bennet JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 6th edn. New York: Churchill Livingstone, 2005; 328-356
19. Nikolaidis P, Vas S, Lawson W et al. Is intraperitoneal tobramycin ototoxic in CAPD patients? Perit Dial Int 1991; 11: 156-161
20. Gendeh BS, Said H, Gibb AG et al. Gentamicin administration via peritoneal dialysis fluid: The risk of ototoxicity. J Laryngol Otol 1991; 105: 999-1001
21. Mars RL, Moles K, Pope K et al. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in endstage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis. Adv Perit Dial 2000; 16: 280-284
22. Van der Hulst RJ, Boeschoten EW, Nielsen FW et al. Otototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. ORL J Otorhinolaryngol Relat Spec 1991; 53: 19-22
23. GendehBS, SaidH, GibbAGet al. Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis. J Laryngol Otol 1993; 107: 681-685 (Pubitemid 23258625)
24. Gendeh BS, Gibb AG, Aziz NS et al. Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngol Head Neck Surg 1998; 118: 551-558 (Pubitemid 28177990)
25. Wu W, Sha S, Schacht J. Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol Neurootol 2002; 7: 171-174 (Pubitemid 34621569)
26. Prescott L, Illingworth R, Critchey J et al. Intravenous Nacetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2: 1097-1100 (Pubitemid 10249121)
27. Arstall M, Yang J, Stafford I et al. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Circulation 1995; 92: 2855-2862
28. Weinbroum A, Rudick V, Ben-Abraham R et al. N-acetyl-L-cysteine for preventing lung reperfusion injury after liver ischemiareperfusion-a possible dual protective mechanism in a dose-response study. Transplantation 2000; 69: 853-859 (Pubitemid 30174110)
29. Tepel M, Van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184 (Pubitemid 30489215)
30. Okur E, Kilinc M, Yildirim I et al. Effect of N-acetylcysteine on carboplatin-induced ototoxicity and nitric oxide levels in a rat model. Laryngoscope 2007; 117: 2183-2186 (Pubitemid 351339594)
31. Theneshkumar S, Lorito G, Giordano P et al. Effect of noise conditioning on cisplatin-induced ototoxicity: a pilot study. Med Sci Monit 2009; 15: 173-177
32. Thomas Dickey D, Muldoon LL, Kraemer DF et al. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 2004; 193: 25-30 (Pubitemid 38813422)
33. Low WK, Sun L, Tan MG et al. L-N-Acetylcysteine protects against radiation-induced apoptosis in a cochlear cell line. Acta Otolaryngol 2008; 128: 440-445 (Pubitemid 351450920)
34. Feldman L, Efrati S, Eviatar E et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72: 359-363 (Pubitemid 47172371)